A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3–4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with serum C-telopeptide (CTx) levels ≤600 ng/L af...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Addison, Christina L., Bouganim, Nathaniel, Hilton, John, Vandermeer, Lisa, Dent, Susan, Amir, Eitan, Hopkins, Sean, Kuchuk, Iryna, Segal, Roanne, Song, Xinni, Gertler, Stan, Mazzarello, Sasha, Dranitsaris, George, Ooi, Daylily, Pond, Gregory, Clemons, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2014
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3962742/
https://ncbi.nlm.nih.gov/pubmed/24638849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-2906-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados